Business Context and Reporting Period
This Form 8-K Current Report was filed by Abbott Laboratories on July 11, 2012. The filing addresses Item 5.02 regarding the departure of a senior officer and the appointment of a successor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly administrative and contains no financial performance data.
Material Changes
The material change reported is a leadership transition within the finance department:
- Departure: Greg W. Linder, Vice President and Controller, will retire effective February 28, 2013.
- Appointment: Robert E. Funck, 51, has been appointed Vice President and Controller, effective March 1, 2013.
Management Commentary and Background
Mr. Funck is a long-tenured employee who joined Abbott in 1987 and became a corporate officer in 2005. His prior roles include:
- Vice President, Chief Ethics and Compliance Officer (2009–2013)
- Vice President, Internal Audit (2007–2009)
- Vice President and Treasurer (2005–2007)
The report does not contain guidance, outlook, risks, contingencies, or unusual items.
Investor Verification Checklist
- Confirm the effective dates of the Controller transition (Feb 28, 2013, and March 1, 2013).
- Verify Mr. Funck's internal track record and tenure within Abbott Laboratories.
- Note that this filing does not impact current financial statements or operational metrics.